Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43857   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-003797-30
    Sponsor's Protocol Code Number:D9180C00003
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2022-02-02
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2021-003797-30
    A.3Full title of the trial
    A Phase III, Multicentre, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of MEDI3506 in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (Oberon)
    Ensayo Fase III, multicéntrico, aleatorizado, doble ciego, de grupos paralelos, dosis crónica y controlado con placebo, para evaluar la eficacia y seguridad de dos dosis de MEDI3506 en pacientes con enfermedad pulmonar obstructiva crónica (EPOC) sintomática y con historial de exacerbaciones de la EPOC (Oberon)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Study to assess efficacy, safety, and tolerability of MEDI3506 in patients with symptomatic chronic obstructive pulmonary disease (COPD) with a history of exacerbations.
    Ensayo para evaluar la eficacia, seguridad y tolerabilidad de MEDI3506 en pacientes con enfermedad pulmonar obstructiva crónica (EPOC) sintomática con antecedentes de exacerbaciones.
    A.3.2Name or abbreviated title of the trial where available
    OBERON
    A.4.1Sponsor's protocol code numberD9180C00003
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAstraZeneca AB
    B.1.3.4CountrySweden
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAstraZeneca AB
    B.4.2CountrySweden
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAstraZeneca Farmacéutica Spain, S.A
    B.5.2Functional name of contact pointUnidad de Investigación Clínica
    B.5.3 Address:
    B.5.3.1Street AddressSerrano Galvache, 56; Parque Norte, Edificio Álamo
    B.5.3.2Town/ cityMadrid
    B.5.3.3Post code28033
    B.5.3.4CountrySpain
    B.5.4Telephone number+3491900200444
    B.5.6E-mailinformacionEECC-Spain@astrazeneca.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code MEDI3506
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNMEDI3506
    D.3.9.1CAS number 2376858-66-9
    D.3.9.2Current sponsor codeMEDI3506
    D.3.9.3Other descriptive namehuman immunoglobulin (Ig) G1 monoclonal antibody (mAb)
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number150
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection
    D.8.4Route of administration of the placeboSubcutaneous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Chronic Obstructive Pulmonary Disease (COPD)
    Enfermedad Pulmonar Obstructiva Crónica (EPOC)
    E.1.1.1Medical condition in easily understood language
    Chronic Obstructive Pulmonary Disease (COPD)
    Enfermedad Pulmonar Obstructiva Crónica (EPOC)
    E.1.1.2Therapeutic area Diseases [C] - Respiratory Tract Diseases [C08]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level PT
    E.1.2Classification code 10009033
    E.1.2Term Chronic obstructive pulmonary disease
    E.1.2System Organ Class 10038738 - Respiratory, thoracic and mediastinal disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the effect of 2 dose regimens of MEDI3506 as add on to standard of care compared with standard of care plus placebo on the rate of moderate to severe exacerbations in former smokers.
    Evaluar el efecto de 2 pautas posológicas de MEDI3506 añadido al tratamiento de base en comparación con el tratamiento de base más placebo en la tasa de exacerbaciones moderadas o graves en exfumadores.
    E.2.2Secondary objectives of the trial
    1. To evaluate the effect of 2 dose regimens of MEDI3506 as add on to standard of care compared with standard of care plus placebo on:

    a) the rate of moderate to severe COPD exacerbations in former and current smokers

    b) time to first moderate to severe COPD exacerbations in former smokers

    c) change in pre-bronchodilator lung function in former smokers

    d) respiratory symptoms in former smokers

    e) respiratory health status/health related quality of life in former smokers

    f) severe COPD exacerbations in former smokers

    g) health status/health-related quality of life in former smokers

    h) COPD-related healthcare resource utilization in former smokers

    i) daily rescue medication use in former smokers

    2.To evaluate the pharmacokinetics and immunogenicity of 2 dose regimens of MEDI3506.

    3. To assess the safety and tolerability of two dose regimen of MEDI3506 as add on to standard of care compared with standard of care plus placebo.
    1. Evaluar el efecto de 2 pautas posológicas de MEDI3506 añadido al tto. de base en comparación con el tto. de base más placebo en:
    a) tasa de exacerbaciones moderadas o graves de la EPOC en exfumadores y fumadores
    b) tiempo hasta las primeras exacerbaciones moderadas o graves de la EPOC en exfumadores
    c) cambio en la función pulmonar pre-broncodilatador en exfumadores
    d) síntomas respiratorios en exfumadores
    e) estado de salud respiratoria/calidad de vida relacionada con la salud en exfumadores
    f) exacerbaciones graves de la EPOC en exfumadores
    g) estado de salud/ calidad de vida relacionada con la salud en exfumadores
    h) uso de recursos sanitarios relacionados con la EPOC en exfumadores
    i) uso diario de medicación de rescate en exfumadores
    2. Evaluar la farmacocinética y la inmunogenicidad de 2 pautas posológicas de MEDI3506
    3. Evaluar la seguridad y tolerabilidad de 2 pautas de MEDI3506 añadido al tratamiento de base en comparación con el tratamiento de base más placebo
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    1. Exploratory nasal epitelial cell biomarker sub-study, 17 September 2021, version 2.0.
    Objective: To evaluate the effect of 2 dose regimens of MEDI3506 as add on to SoC compared with SoC plus placebo on overall biomarker transcript levels in nasal epithelial cells, including use of baseline biomarker levels to predict treatment response.

    2. Exploratory spontaneous sputum sub-study, 25 October 2021, version 2.0.
    Objective: To evaluate the pharmacodynamic effects of MEDI3506 compared with SoC plus placebo on airway epithelial mucin secretion, including use of baseline mucin levels to predict treatment response.
    1. Subestudio exploratorio de biomarcadores de células epiteliales nasales, 17 de septiembre de 2021, versión 2.0.
    Objetivo: Evaluar el efecto de 2 pautas posológicas de MEDI3506 añadido al tratamiento de base en comparación con el tratamiento de base más placebo en los niveles generales de biomarcadores de transcripción en células epiteliales nasales, incluido el uso de niveles de biomarcadores iniciales para predecir la respuesta al tratamiento.

    2. Subestudio exploratorio de esputo espontáneo, 25 de octubre de 2021, versión 2.0.
    Objetivo: Evaluar los efectos farmacodinámicos de MEDI3506 en comparación con el tratamiento de base más placebo sobre la secreción de mucina epitelial de las vías respiratorias, incluido el uso de niveles de mucina iniciales para predecir la respuesta al tratamiento.
    E.3Principal inclusion criteria
    1. Participant must be ≥ 40 years of age and capable of giving signed informed consent.

    2. Documented diagnosis of COPD for at least one year prior to enrolment.

    3. Post BD FEV1/FVC < 0.70 and post-BD FEV1 >20% of predicted normal value.

    4. Documented history of ≥ 2 moderate or ≥ 1 severe COPD exacerbations within 12 months prior to enrolment.

    5. Documented optimized dual or triple treatment with COPD and at a stable dose for at least 3 months prior to enrolment.

    6. Smoking history of ≥ 10 pack-years.

    7. CAT total score ≥10, with each of the phlegm (sputum) and cough items ≥ 2.
    1. El participante debe tener ≥40 años de edad y ser capaz de otorgar un consentimiento informado firmado.

    2. Diagnóstico documentado de EPOC durante al menos un año antes de la inclusión.

    3. VEF1/CVF post-BD <0,70 y VEF1 post-BD >20 % del valor normal previsto.

    4. Antecedentes documentados de ≥2 exacerbaciones moderadas o ≥1 exacerbación grave de la EPOC en los 12 meses anteriores a la inscripción.

    5. Tratamiento triple, o doble optimizado documentado para la EPOC y a una dosis estable durante al menos 3 meses antes de la inscripción.

    6. Antecedentes de tabaquismo de ≥10 paquetes-año.

    7. Puntuación total del cuestionario de evaluación de la EPOC (COPD Assessment Test, CAT) ≥10, con los ítems de flema (esputo) y tos ≥2 cada uno.
    E.4Principal exclusion criteria
    1. Clinically important pulmonary disease other than COPD.

    2. Radiological findings suggestive of a respiratory disease other than COPD that is contributing to the participant’s respiratory symptoms.

    3. Current diagnosis of asthma, prior history of asthma, or asthma-COPD overlap. Childhood history of asthma is allowed and defined as asthma diagnosed and resolved before the age of 18.

    4. Any unstable disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric disorder, major physical and/or cognitive impairment that could affect safety, study findings or participants ability to complete the study.

    5. COPD exacerbation, within 2 weeks prior to randomization, that was treated with systemic corticosteroids and/or antibiotics, and/or led to hospitalization.

    6. Active significant infection within the 4 weeks prior to randomization, pneumonia within 6 weeks prior to randomization, or medical condition that predisposes the participant to infection.

    7. Suspicion of, or confirmed, ongoing SARS-CoV-2 infection.

    8. Significant COVID-19 illness within the 6 months prior to enrolment.

    9. Unstable cardiovascular disorder.

    10. Diagnosis of cor pulmonale, pulmonary arterial hypertension and/or right ventricular failure.

    11. History of known immunodeficiency disorder, including a positive test for HIV-1 or HIV 2.

    12. History of positive test or treatment for hepatitis B or hepatitis C.

    13. Evidence of active liver disease, including jaundice during screening.

    14. Malignancy, current or within the past 5 years, except for adequately treated non-invasive basal cell and squamous cell carcinoma of the skin and cervical carcinoma-in-situ treated with apparent success more than one year prior to enrolment. Suspected malignancy or undefined neoplasms.

    15. Participants who have evidence of active TB.

    16. Participants that have previously received MEDI3506.

    17. Any clinically significant abnormal findings in physical examination, vital signs, ECG, or laboratory testing during the screening period, which in the opinion of the investigator may put the participant at risk because of their participation in the study, or may influence the results of the study, or the participant’s ability to complete the entire duration of the study.

    18. Active vaping of any products within the 6 months prior to randomization and during the study.
    1. Enfermedad pulmonar clínicamente importante distinta de la EPOC.
    2. Hallazgos radiológicos indicativos de una enfermedad respiratoria distinta de la EPOC que contribuye a los síntomas respiratorios del participante.
    3. Diagnóstico actual de asma, antecedentes de asma o solapamiento asma-EPOC. Se permiten los antecedentes infantiles de asma, definidos como asma diagnosticada y resuelta antes de los 18 años de edad.
    4. Cualquier trastorno inestable, incluidos, entre otros, trastornos cardiovasculares, gastrointestinales, hepáticos, renales, neurológicos, musculoesqueléticos, infecciosos, endocrinos, metabólicos, hematológicos o psiquiátricos, así como cualquier deterioro físico y/o cognitivo importante que pudiera afectar a la seguridad, los hallazgos del estudio o la capacidad de los participantes para completar el estudio.
    5. Exacerbación de la EPOC, en las 2 semanas anteriores a la aleatorización, que se trató con corticoesteroides y/o antibióticos sistémicos, y/o provocó una hospitalización.
    6. Infección activa significativa en las 4 semanas anteriores a la aleatorización, neumonía en las 6 semanas anteriores a la aleatorización o afección médica que predispone al participante a contraer infecciones.
    7. Sospecha o confirmación de infección activa por SARS-CoV-2.
    8. Enfermedad por COVID-19 significativa en los 6 meses anteriores a la inscripción.
    9. Trastorno cardiovascular inestable.
    10. Diagnóstico de cardiopatía pulmonar, hipertensión arterial pulmonar y/o insuficiencia ventricular derecha.
    11. Antecedentes de un trastorno de inmunodeficiencia conocido, incluida una prueba positiva para VIH-1 o VIH-2.
    12. Antecedentes de resultado positivo o tratamiento para la hepatitis B o C.
    13. Indicios de enfermedad hepática activa, incluida la ictericia durante la selección.
    14. Neoplasia maligna, actual o en los últimos 5 años, excepto los carcinomas basocelular y epidermoide de la piel no invasivos tratados adecuadamente y el carcinoma de cuello uterino localizado tratado con éxito aparente más de un año antes de la inscripción. Sospecha de neoplasia maligna o neoplasias no definidas.
    15. Participantes con indicios de TB activa.
    16. Participantes que han recibido previamente MEDI3506.
    17. Cualquier hallazgo anómalo clínicamente significativo en la exploración física, las constantes vitales, el ECG o las pruebas analíticas durante el periodo de selección que, en opinión del investigador, pueda poner en riesgo al participante debido a su participación en el estudio, o que pueda influir en los resultados del estudio, o en la capacidad del participante para completar la totalidad del estudio.
    18. Vapeo activo de cualquier producto en los 6 meses anteriores a la aleatorización y durante el estudio.
    E.5 End points
    E.5.1Primary end point(s)
    Annualized rate of moderate to severe COPD exacerbations in participants who are former smokers.
    Tasa anualizada de exacerbaciones moderadas o graves de la EPOC en participantes que son exfumadores.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Week 52.
    Semana 52.
    E.5.2Secondary end point(s)
    1. Annualized rate of moderate to severe COPD exacerbations in former or current smokers

    2. Time to first moderate to severe COPD exacerbation in former smokers

    3. Change from baseline in pre-bronchodilator, pre dose trough FEV1 (mL) in former smokers

    4. Change from baseline in E-RS:COPD total score in former smokers

    5. Change from baseline in SGRQ total score in former smokers

    6. Time to first severe COPD exacerbation in former smokers

    7. Annualized rate of severe COPD exacerbations in former smokers

    8. Change from baseline in CAT total score in former smokers

    9. Proportion of participants achieving MCID in CAT score in former smokers

    10. Proportion of participants having ≥ 1 healthcare resource utilization type in former smokers

    11. Annualized rate of healthcare resource utilization in former smokers

    12. Change from baseline in rescue medication in former smokers

    13. Trough serum concentrations of MEDI3506

    14. Presence of anti-drug antibodies

    15. Safety and tolerability
    1. Tasa anualizada de exacerbaciones moderadas o graves de la EPOC en exfumadores o fumadores actuales
    2. Tiempo hasta la primera exacerbación moderada o grave de la EPOC en exfumadores
    3. Cambio con respecto al inicio en el VEF1 (ml) mínimo previo al broncodilatador y previo a la dosis en exfumadores
    4. Cambio con respecto al inicio en la puntuación total del cuestionario de Evaluación de los síntomas respiratorios en la EPOC (Evaluating Respiratory Symptoms in COPD, E-RS:COPD) en exfumadores
    5. Cambio con respecto al inicio en la puntuación total del cuestionario respiratorio St. George (St. George Respiratory Questionnaire, SGRQ) en exfumadores
    6. Tiempo transcurrido hasta la primera exacerbación grave de la EPOC en exfumadores
    7. Tasa anualizada de exacerbaciones graves de la EPOC en exfumadores
    8. Cambio con respecto al inicio en la puntuación total del CAT en exfumadores
    9. Proporción de participantes que logran una diferencia mínima clínicamente importante (DMCI) en la puntuación CAT en exfumadores
    10. Proporción de participantes que presentan ≥1 tipo de utilización de recursos sanitarios en exfumadores
    11. Tasa anualizada de utilización de recursos sanitarios en exfumadores
    12. Cambio con respecto al inicio en la medicación de rescate en exfumadores
    13. Concentraciones séricas mínimas de MEDI3506
    14. Presencia de anticuerpos antifármaco
    15. Seguridad y tolerabilidad
    E.5.2.1Timepoint(s) of evaluation of this end point
    Over 52 weeks.
    En el plazo de 52 semanas.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic Yes
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned8
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA86
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Belgium
    Bulgaria
    Canada
    Czechia
    Denmark
    Finland
    Hungary
    India
    Japan
    Korea, Democratic People's Republic of
    Mexico
    Netherlands
    Norway
    Portugal
    Spain
    Sweden
    Turkey
    United States
    Viet Nam
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Last subject last visit (LSLV)
    LSLV
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months2
    E.8.9.1In the Member State concerned days16
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months8
    E.8.9.2In all countries concerned by the trial days21
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 622
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 650
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state66
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 534
    F.4.2.2In the whole clinical trial 1272
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Participants who complete a 52-week study treatment period, and have not been prematurely discontinued from IP, may be offered an opportunity to enter a controlled long term extension study.
    A los participantes que completen un periodo de tratamiento del estudio de 52 semanas y no hayan interrumpido de forma prematura el PEI se les puede ofrecer la oportunidad de entrar en un estudio de extensión controlado a largo plazo.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2022-04-04
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2022-03-22
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Apr 24 19:36:27 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA